Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
Date:7/28/2009

DETROIT, July 28 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) recorded net sales of $48.1 million in the first quarter of Fiscal 2010, ended June 30, 2009, compared to $108.3 million during the corresponding period of Fiscal 2009. The reduction in sales was primarily due to reduced sales of Para IV products in the current period, as compared to the corresponding period of Fiscal 2009. Sales of distributed products were also lower due to price erosion on the products sold, partially offset by new product launches. Caraco's manufactured product sales in the first quarter of Fiscal 2010 were lower due to the negative impact of our voluntary recalls of certain products, and, in part, the FDA's seizure of certain of our inventory and cessation of manufacturing, as previously disclosed. We incurred a net pre-tax loss of $14.4 million during the first quarter of Fiscal 2010, as compared to net pre-tax income of $14.6 million during the corresponding period of Fiscal 2009. The net pre tax loss was primarily due to the creation of an inventory reserve relating to the inventory seized by the FDA, as well as lower sales.

Dan Movens, Caraco's Chief Executive Officer, said, "As previously disclosed, on June 25, 2009, the FDA seized drug products manufactured in our Michigan facilities. The seizure also included ingredients held at these same facilities. The FDA's most recent inspection of Caraco's Detroit facility, completed in May 2009, found observations of potential unresolved violations of cGMP requirements as previously disclosed in our last SEC filing on Form 10-K for the fiscal year ended March 31, 2009, filed on June 15, 2009. The Company believes that corrective actions have been made and continual improvements are in process. We are working with consultants to further define and correct any
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... UT (PRWEB) August 28, 2014 CMMI (Center ... coordination and integration of care to address patient needs. What ... quality of care outcomes (with more provider accountability) and reduce ... all the people involved in the care of a patient ... figure out how to distribute it. If it sounds complicated, ...
(Date:8/28/2014)... August 28, 2014 GreenRushReview.com, a ... recently launched a “Video” section located at ... information on various cannabis companies in video format. ... an assortment of news clips, interviews, and other ... A portion of the videos can also be ...
(Date:8/28/2014)... August 28, 2014 Genetic testing ... throughout the world, with large reference laboratories as ... laboratories differ with regard to the genetic variants ... payers may struggle to find the most appropriate ... help clients sort through these differences, Hayes, Inc. ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 On September ... interview Stephen Isaacs, the chairperson, president and CEO of ... Meet the Mesothelioma Experts live broadcast. The ... director and mesothelioma expert nurse practitioner, Mary Hesdorffer, ... will be Aduro BioTech’s experimental therapy for malignant pleural ...
(Date:8/28/2014)... The Foundation for Women’s Cancer ... by alerting women to the link between obesity and ... of endometrial cancer. , Endometrial cancer is the ... cancer. More than 52,600 will learn of a diagnosis ... with weight management challenges to know the early warning ...
Breaking Medicine News(10 mins):Health News:Med-Certification.com Expects Industry "Hiccups" with New Models for Patient Care and Reimbursement 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 3Health News:Foundation for Women's Cancer Alerts Women to Link Between Obesity and Endometrial Cancer 2
... A study published in the October 15 issue ... the Cleveland Adolescent Sleepiness Questionnaire (CASQ), a new self-completed ... The study, led by James C. Spilsbury, PhD, of ... Ohio, focused on a subsample of 411 adolescents between ...
... 11:30 am EDT, TEL AVIV, Israel, October 15 ... that it has signed,an agreement to acquire 100% of ... Blessing Biotech GmbH (together the "Gewurzmuller,Group"), in consideration for ... The Company will be hosting a conference call ...
... Island Hospital and Brown University researchers reported that 18 percent ... initial psychiatric clearance for the surgery. The study is the ... for surgery, and the largest to determine the percentage of ... exclusion. It was published in the October edition of the ...
... of ills such as heart disease , , SUNDAY, ... collections of genetic and clinical data available free to ... Institutes of Health. , The Web-based SHARe (SNP Health ... from a number of large population-based studies, starting with ...
... breathing disorder, arterial trouble , FRIDAY, Oct. 12 (HealthDay ... airway pressure (CPAP) to treat people with obstructive sleep ... of the arteries -- within months, a new study ... of a direct link between obstructive sleep apnea and ...
... BEACH, Calif., Oct. 12 History,will be written if ... Act during a vote scheduled for next week. It ... law regarding swimming pool and spa safety.,The National Drowning ... but with wording similar to HR 1721 passed on ...
Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007 2Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2Health News:U.S. Unveils Database of Genetic, Clinical Research 2Health News:Sleep Apnea Treatment Helps Stave Off Heart Disease 2Health News:NDPA Urges Passage of Historic Pool Bill 2
(Date:8/28/2014)... , Aug. 28, 2014   RapidForce , ... announced today a strategic partnership with professional tennis player ... tennis player, Isner wears RapidForce during competitions to help ... competes this week at the 2014 US Open Tennis ... tape, RapidForce Physio Hybrid Shapes are a revolutionary hybrid ...
(Date:8/28/2014)... 28. August 2014 Sequent ... der Patientenrekrutierung für eine IDE-Pivot-Studie („IDE" ... Beurteilung der Sicherheit und Wirksamkeit des ... („WEB") bekanntgegeben. Adam Arthur, MD, Dozent an ... Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der WEB-IT-Studie, ...
(Date:8/28/2014)... ALISO VIEJO , Californie, 28 ... Inc. a annoncé aujourd,hui le début ... cadre d,une étude  d,exemption des dispositifs ... anglais) destinée à évaluer l,innocuité et ... anévrismes (« WEB »). Le docteur Adam ...
Breaking Medicine Technology:America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 2America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 3America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 4Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 3Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 4
... (Nasdaq: PRGO ; TASE) today announced that it ... foam brought by Stiefel Research Australia Pty. Ltd., a GSK ... in the U. S., a generic version of Men,s Rogaine® ... Rogaine® (Minoxidil) Foam is used to regrow ...
... Informex , the leading meeting place for buyers ... applications, today announced details of its second Latin American Green ... The event will be held in September 2011, with further ... 2011 event follows the success of the inaugural Informex Latin ...
Cached Medicine Technology:Perrigo Announces Settlement of Rogaine® Foam Patent Litigation 2Second Annual Latin America 'Green Exchange Conference' Hosted by Informex Focuses on a Sustainable Future for Chemistry 2Second Annual Latin America 'Green Exchange Conference' Hosted by Informex Focuses on a Sustainable Future for Chemistry 3
... the semi-quantitative determination of specific IgA autoantibodies ... of the anti-Gliadin IgA assay can be ... of diseases associated with elevated levels of ... these autoantibodies are one indicator in a ...
... ADVIA Urinalysis WorkCell System - A ... tests per hour, with true load-and-go ... of Clinitek Atlas and UF-100 for ... regarded systems working together deliver utmost ...
... (EIA) test kit is to be used ... in human serum during the second half ... (unconjugated) procedure is an enzyme immunoassay which ... binding. In the procedure, estriol is ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
Medicine Products: